Literature DB >> 12913001

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.

Birke Bartosch1, Alessandra Vitelli, Christelle Granier, Caroline Goujon, Jean Dubuisson, Simona Pascale, Elisa Scarselli, Riccardo Cortese, Alfredo Nicosia, François-Loïc Cosset.   

Abstract

Several cell surface molecules have been proposed as receptor candidates, mediating cell entry of hepatitis C virus (HCV) on the basis of their physical association with virions or with soluble HCV E2 glycoproteins. However, due to the lack of infectious HCV particles, evidence that these receptor candidates support infection was missing. Using our recently described infectious HCV pseudotype particles (HCVpp) that display functional E1E2 glycoprotein complexes, here we show that HCV is a pH-dependent virus, implying that its receptor component(s) mediate virion internalization by endocytosis. Expression of the CD81 tetraspanin in non-permissive CD81-negative hepato-carcinoma cells was sufficient to restore susceptibility to HCVpp infection, confirming its critical role as a cell attachment factor. As a cell surface molecule likely to mediate endosomal trafficking, we demonstrate that the human scavenger receptor class B type 1 (SR-B1), a high-density lipoprotein-internalization molecule that we previously proposed as a novel HCV receptor candidate due to its affinity with E2 glycoproteins, is required for infection of CD81-expressing hepatic cells. By receptor competition assays, we found that SR-B1 antibodies that blocked binding of soluble E2 could prevent HCVpp infectivity. Furthermore, we establish that the hyper-variable region 1 of the HCV E2 glycoprotein is a critical determinant mediating entry in SR-B1-positive cells. Finally, by correlating expression of HCV receptors and infectivity, we suggest that, besides CD81 and SR-B1, additional hepatocyte-specific co-factor(s) are necessary for HCV entry.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913001     DOI: 10.1074/jbc.M305289200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  239 in total

1.  Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus.

Authors:  Fumi Kobayashi; Shuhei Yamada; Shuhei Taguwa; Chikako Kataoka; Satomi Naito; Yoshiki Hama; Hideki Tani; Yoshiharu Matsuura; Kazuyuki Sugahara
Journal:  Glycoconj J       Date:  2012-06-03       Impact factor: 2.916

2.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

3.  A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

Authors:  Philip Meuleman; Maria Teresa Catanese; Lieven Verhoye; Isabelle Desombere; Ali Farhoudi; Christopher T Jones; Timothy Sheahan; Katarzyna Grzyb; Riccardo Cortese; Charles M Rice; Geert Leroux-Roels; Alfredo Nicosia
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

4.  Hepatitis C virus infection of human T lymphocytes is mediated by CD5.

Authors:  Mohammed A Sarhan; Tram N Q Pham; Annie Y Chen; Tomasz I Michalak
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

5.  Coronavirus and influenza virus proteolytic priming takes place in tetraspanin-enriched membrane microdomains.

Authors:  James T Earnest; Michael P Hantak; Jung-Eun Park; Tom Gallagher
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

6.  Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Authors:  Yong Wang; Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Fraser Conrad; Jianlong Lou; Michael Eckart; James D Marks; Steven K H Foung
Journal:  J Biol Chem       Date:  2011-10-14       Impact factor: 5.157

7.  Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.

Authors:  Mark S Sulkowski; Minhee Kang; Roy Matining; David Wyles; Victoria A Johnson; Gene D Morse; Valerianna Amorosa; Debika Bhattacharya; Kristine Coughlin; Flossie Wong-Staal; Marshall J Glesby
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

8.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  CLA-1 and its splicing variant CLA-2 mediate bacterial adhesion and cytosolic bacterial invasion in mammalian cells.

Authors:  Tatyana G Vishnyakova; Roger Kurlander; Alexander V Bocharov; Irina N Baranova; Zhigang Chen; Mones S Abu-Asab; Maria Tsokos; Daniela Malide; Federica Basso; Alan Remaley; Gyorgy Csako; Thomas L Eggerman; Amy P Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-27       Impact factor: 11.205

10.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.